Blue Earth Diagnostics Announces Upcoming Presentations from FALCON Study of Axumin® at ASCO GU 2020

San Francisco, CA (UroToday.com) -- Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced upcoming presentations of additional analyses from the FALCON clinical trial (NCT02578940) of Axumin ® (fluciclovine F18) injection), which evaluated its impact on the management of patients with recurrent prostate cancer. The presentations are part of the scientific programs for the ASCO 2020 Genitourinary Cancers Symposium (ASCO GU), February 13 – 15, 2020, in San Francisco, Calif., and the Radiation Oncology Summit: ACRO 2020, February 26 – 29, 2020, in Fort Lauderdale, Fla. Details of the presentations to be given by Blue Earth Diagnostics and its collaborators are listed below.

Blue Earth Diagnostics also provided an update that full results from the FALCON study will be published in an upcoming issue of the International Journal of Radiation Oncology, Biology, Physics.

ASCO 2020 Genitourinary Cancers Symposium (ASCO GU), February 13–15, 2020

     

Date:

 

Thursday, February 13, 2020 11:30 a.m. − 1:00 p.m. and 5:30 − 6:30 p.m. PT

Presentation:

 

Impact of 18F-fluciclovine PET on salvage radiotherapy plans for men with post-radical prostatectomy recurrence of prostate cancer

Abstract Number:

 

19

Presenter:

 

Professor Heather Payne, FRCP, FRCR, University College Hospital, London

     

Session Title & Times:

 

Prostate Cancer and Trials in Progress

Poster Session A:

 

Prostate Cancer, Board A7

   

11:30 a.m. – 1 p.m., 5:15 – 6:15 p.m. PT

     

Location:

 

Moscone West Building, San Francisco, Calif.

Blue Earth Diagnostics invites participants at the ASCO Genitourinary (GU) Cancers Symposium 2020 to attend the presentation above and to visit the company at Exhibit Booth 46.

Radiation Oncology Summit: ACRO 2020, February 26 – 29, 2020, Fort Lauderdale, Fla.

     

Date:

 

Saturday, February 29, 2020

Presentation:

 

The impact of prior prostatectomy on the detection of prostate cancer recurrence with 18F-fluciclovine: Imaging results from the FALCON trial

Abstract Number:

 

20

Presenter:

 

Eugene Teoh, MD, Blue Earth Diagnostics (Oxford University Hospitals NHS Trust at time of study)

     

Session Title & Times:

 

Poster Presentations

   

8:00 a.m. – 1:30 p.m. ET

     

Location:

 

Westin Fort Lauderdale Beach Foyer, Las Olas ballrooms, Fort Lauderdale, Fla.

Blue Earth Diagnostics invites participants at ACRO 2020 to attend the presentation above and to visit the company at Exhibit Booth 27. The company is also hosting a satellite symposium event, “Detecting and Localizing Recurrent Prostate Cancer with Axumin ® (fluciclovine F 18),” with invited speaker Dr. Steven Finkelstein, MD, DABR, FACRO, Florida Cancer Affiliates, US Oncology Network, which will be held on Thursday, February 27, 2020, from 12:00 – 1:00 p.m. ET, in the Rio Vista room.

NOTE: Axumin ® (fluciclovine F 18) injection is FDA-approved for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment

Source: "Blue Earth Diagnostics Announces Upcoming Presentations From FALCON Study Of Axumin® (Fluciclovine F18) PET/CT Impact On Clinical Management Of Recurrent Prostate Cancer". 2020. AP NEWS

email news signup